23Ingredients Menu Improves Physical and Mental Health BOULDER, Colo.–(BUSINESS WIRE)–When Alexia Parks won the first of six contracts to prepare and deliver 1-million meals to 350 sheltered homeless in Riverside County, CA, Parks knew that her bid was higher than that of a competing global food catering company. What the global company did not know … [Read more…]
A Bill & Melinda Gates Foundation grant will be used to expand research and development of OVX836 in a wide range of seasonal and highly pathogenic influenza strains Osivax continues evaluating OVX836 across several phase 2 clinical trials in healthy volunteers LYON, France–(BUSINESS WIRE)–Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly … [Read more…]
– JK07 Advancing into Phase 2 Clinical Trial in Heart Failure with Reduced Ejection Fraction (HFrEF); Topline Phase 1b Results Expected in 1H 2023 – –Fourth Cohort Enrolling in Phase 1/2 Study Evaluating JK08 Monotherapy in Advanced Solid Tumors; Favorable Pharmacodynamic Activities Observed Across Cohorts – GAITHERSBURG, Md.–(BUSINESS WIRE)–Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Minimal Residual Disease Testing Market Size, Share & Trends Analysis Report By Technology (NGS, PCR), Cancer Type (Hematological Malignancy), By End-use (Hospitals), By Region, And Segment Forecasts, 2023 – 2030” report has been added to ResearchAndMarkets.com’s offering. The global minimal residual disease testing market size is expected to reach USD 4.50 billion by … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Europe Cell and Gene Therapy Market – Focused Insights 2023-2028” report has been added to ResearchAndMarkets.com’s offering. This report offers market size & forecast data for cell & gene therapy market in Europe. The report covers commercial cell & gene therapy products, such as conventional cell therapies, CAR-T cell therapies, gene therapies, cell-based … [Read more…]
LOS ANGELES–(BUSINESS WIRE)–#COVID19–As countries continue to negotiate a new Pandemic Accord, AHF cautions that if the new global public health instrument becomes an opt-in-only treaty, it will be less effective in protecting the world from outbreaks like COVID-19. “You cannot opt out of global public health because it is a global good – we all … [Read more…]
GENT, Belgium & MALVERN, Pa. & TOKYO–(BUSINESS WIRE)–#IVD–H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G NfL CSF and Lumipulse G NfL Blood assays for the fully automated random-access LUMIPULSE® G immunoassay systems. These CLEIA (chemiluminescent enzyme immunoassay) assays allow for the quantitative measurement of Neurofilament light … [Read more…]
VC to back startups at the intersection of biology, data and computation Partners Edward Kliphuis and Simon Turner will lead the new investment strategy, deploying their extensive experience in the sector Sofinnova Digital Medicine is the sixth and newest addition to Sofinnova’s multi-fund platform of investment strategies spanning the life sciences sector from seed to … [Read more…]
GUANGZHOU, China–(BUSINESS WIRE)–Guangzhou, one of the most developed Chinese cities, is building a communication and cooperation platform for Asian youth. Asia Youth Leaders Forum opened on March 25. Nearly 400 guests and youth representatives from Asian countries have gathered in Nansha to discuss how to enhance youth cooperation, strengthen common values, and promote the peace … [Read more…]
Recent CAN008 Phase 1 Follow-Up Data Showed 67% 5-Year Overall Survival in High-Dose Cohort, Reported at ESMO Sarcoma and Rare Cancers BEIJING, China & BURLINGTON, Mass.–(BUSINESS WIRE)–CANbridge Pharmaceuticals, Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies to treat rare diseases and oncology, … [Read more…]
